Biocon Limited

Equities

BIOCON

INE376G01013

Biotechnology & Medical Research

Market Closed - NSE India S.E. 08:01:59 2024-03-28 am EDT 5-day change 1st Jan Change
264.2 INR +2.94% Intraday chart for Biocon Limited +7.01% +5.81%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion MT
Biocon's CFO Resigns MT
Biocon Limited Accepts Resignation of Indranil Sen as Chief Financial Officer CI
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics MT
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million RE
Biocon Limited Announces Executive Appointments CI
Biocon Arm to Launch Colorectal Cancer Biosimilar in Canada MT
Bristol Myers CEO says India to have largest R&D presence outside US by 2025 RE
INDIA STOCKS-Indian shares muted after five-session rally, tracking Asian peers RE
Jefferies Adjusts Biocon’s Price Target to INR250 From INR255, Keeps at Hold MT
Biocon Swings to Profit in Fiscal Q3 MT
Transcript : Biocon Limited, Q3 2024 Earnings Call, Feb 09, 2024
Indian shares set for a muted start, tracking Asian peers RE
Biocon CFO Resigns MT
India's Biocon posts profit on biosimilar boost, divestment gains; CFO resigns RE
Biocon Limited Announces Indranil Sen Resigns as Chief Financial Officer, Effective March 15, 2024 CI
Biocon Limited Announces Nehal Vora Resigns as Commercial Head, Effective March 31, 2024 CI
Biocon Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
CVS will remove AbbVie's Humira from some drug reimbursement lists in April RE
Biocon Limited Announces the Resignation of Prasad Deshpande as Head­ SCM and Central Engineering, Senior Management Personnel, Effective January 16, 2024 CI
Biocon's Biologics Arm Completes Integration of Viatris Biosimilar Business in 120 Countries MT
India's Nifty set to open flat as global rally cools RE
Biocon Reportedly Evaluating Plan to Sell Its Generic Active Pharmaceutical Ingredient Business CI
Biocon Denies Plans to Sell $1.5 Billion Generic API Business CI
India's Nifty set to hit new high as dovish Fed triggers global rally RE
Chart Biocon Limited
More charts
Biocon Limited is an India-based biopharmaceutical company, which focuses on treating diabetes, cancer and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. It has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. It has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
18
Last Close Price
264.2 INR
Average target price
281 INR
Spread / Average Target
+6.38%
Consensus
  1. Stock
  2. Equities
  3. Stock Biocon Limited - NSE India S.E.
  4. News Biocon Limited
  5. Biocon : Unit Gets European Commission's Approval for Biosimilar of Cancer Drug